子宫内膜癌辅助治疗模式的Meta分析

doi:10.3969/j.issn.1006-5253.2016.05.005

摘要
图/表
参考文献
相关文章 (4)

全文: PDF (1473 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的系统评价化疗和放疗两种辅助治疗方案在子宫内膜癌患者术后的应用效果。方法计算机检索2006—2016年Cochrane Library、Medline、PubMed、Ovid、Embase、维普中文科技期刊全文数据库、中国期刊全文数据库、万方数据库、中国生物医学文献数据库等中术后单纯化疗与术后单纯放疗治疗子宫内膜癌的随机对照试验(RCTs),采用RevMan5.2软件进行Meta分析。结果共纳入1 828名患者8项RCTs。Meta分析结果显示:术后单纯化疗治疗子宫内膜癌的5年总生存率(RR＝0.92,95%CI:0.87~0.98)、复发率(RR＝1.15,95%CI:1.02~1.30)均优于单纯放疗,而发生3/4级血小板减少症(RR＝0.13,95%CI:0.07~0.27)、3/4级中性粒细胞减少症(RR＝0.01,95%CI:0.00~0.03)均高于单纯放疗。结论与术后单纯放疗相比,术后单纯化疗对于子宫内膜癌患者,能有效提高其生存率,并降低复发率,但副作用较大。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈巧英
	蒋本贵

关键词 ：放疗, 化疗, 子宫内膜癌, 辅助治疗, Meta分析

Abstract：Objective To review the effect and safety of chemotherapy alone or radiation alone in the treatment of endometrial cancer. Methods Databases of PubMed, Cochrane Library, Medline, Embase, Ovid, CBM, VIP, Wanfang, CNKI were searched, and randomized trials (RCT) of chemotherapy alone versus radiation alone for the treatment of endometrial cancer were gathered (from 2006 to 2016). Then the Meta-analysis was performed by using RevMan 5.2 software. Results Eight RCTs were included, involving 1 828 patients. Meta-analysis indicated that the differences of 5-year overall survival rate (RR＝0.92,95%CI (0.87,0.98), P=0.01), disease recurrence rate (RR＝1.15,95%CI (1.02,1.30), P=0.02), grade 3/4 thrombocytopenia (RR＝0.13,95%CI (0.07,0.27), P<0.000 01), grade 3/4 neutropenia (RR＝0.01,95%CI (0.00,0.03), P<0.000 01) between chemotherapy alone and radiation alone were significant. Conclusion Compared with postoperative radiotherapy, postoperative chemotherapy might improve the overall survival rate for patients with advanced stage endometrial cancer.

Key words： radiotherapy chemotherapy endometrial cancer adjuvant therapy Meta analysis

收稿日期: 2016-09-12

通讯作者: 陈巧英,Email:meiyanrv@163.com

引用本文:

陈巧英，蒋本贵. 子宫内膜癌辅助治疗模式的Meta分析[J]. 中国医院统计, 2016, 23(5): 335-339.
Chen Qiaoying, Jiang Bengui. Effectiveness of chemotherapy alone versus radiation alone in endometrial cancer Meta analysis of randomized controlled trials. journal1, 2016, 23(5): 335-339.

链接本文:

http://manu58.magtech.com.cn/Jwk_zgyytj/CN/10.3969/j.issn.1006-5253.2016.05.005 或 http://manu58.magtech.com.cn/Jwk_zgyytj/CN/Y2016/V23/I5/335

[1] GETZ G, GABRIEL S B, CIBULSKIS K, et al. Integrated genomic characterization of endometrial carcinoma[J]. Nature, 2014,497(7447):67-73.
[2] MURALI R, SOSLOW R A, WEIGELT B. Classification of endometrial carcinoma: more than two types[J]. Lancet Oncol, 2014,15(7):268-278.
[3] 刘瑶,王玉东.子宫内膜癌的孕激素拮抗及增敏机制[J].国际妇产科学杂志,2015,42(1):104-107.
[4] 孙馥箐,段华.子宫内膜癌保留生育功能治疗的现状与存在的问题[J].中国微创外科杂志,2015,6(1):73-76.
[5] GAO C, WANG Y, TIAN W, et al. The therapeutic significance of aromatase inhibitors in endometrial carcinoma[J].Gynecol Oncol, 2014,134(1):190-195.
[6] RANDALL ME, FILIACI VL, MUSS H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study[J]. J Clin Oncol. 2006,24(1):36-44.
[7] MAGGI R, LISSONI A, SPINA F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial[J]. Br J Cancer. 2006,95(3):266-271.
[8] SUSUMU N, SAGAE S, UDAGAWA Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate-and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study[J]. Gynecol Oncol, 2008,108(1):226-233.
[9] 田芬, 张莉华,卢静.晚期子宫内膜癌的治疗效果及预后研究[J].河北医药,2009,31(3):279-280.
[10]施春明.高危早期子宫内膜癌术后辅助放疗与化疗的疗效比较[J].现代肿瘤医学,2013,21(9):2066-2068.
[11]高新萍,梁义娟,王佩然,等.晚期子宫内膜癌不同辅助治疗方式的预后情况分析[J].中国妇幼保健,2014,29(17):2712-2714.
[12]SIGNORELLI M, LISSONI AA, DE PE, et al. Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer[J]. J Gynecol Oncol, 2015,26(4):284-292.
[13]BOOTHE D, ORTON A, ODEI B, et al. Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: patterns of care and impact on overall survival[J]. Gynecol Oncol, 2016,141(3):421-427.
[14]KUPPETS R, LE T, LE T, et al. The Role of Adjuvant Therapy in Endometrial Cancer[J]. J Obstet Gynaecol Can, 2013,35(4):375-379.
[15]GADDUCCI A, GRECO C. The evolving role of adjuvant therapy in endometrial cancer[J]. Crit Rev Oncol Hematol, 2011,78(2):79-91.
[16]RABINOVICH A. Neo-adjuvant chemotherapy for advanced stage endometrial carcinoma: a glimmer of hope in select patients[J]. Arch Gynecol Obstet, 2015,293(1):47-53.
[17]HOGBERG T, SIGNORELLI M, OLIVEIRA CFD, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-Results from two randomised studies[J]. Eur J Cancer, 2010,46(13):2422-2431.
[18]FOERSTER R, KLUCK R, RIEF H, et al. Survival of women with clear cell and papillary serous endometrial cancer after adjuvant radiotherapy[J]. Radiat Oncol, 2014,9(1):141-146.
[19]LEE L J, BU P, FELTMATE C, et al. Adjuvant chemotherapy with external beamradiation therapy for high-grade, node-positive endometrial cancer[J]. Int J Gynecol Cancer, 2014,24(8):1441-1448.
[20]KOBGg A, SIMERA I, COLLINGWOOD M, et al. Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis. Ann Oncol[J]. Ann Oncol, 2007,18(10):1595-1604.